<DOC>
	<DOCNO>NCT01807364</DOCNO>
	<brief_summary>Treatment glucocorticoid mineralocorticoid change congenital adrenal hyperplasia ( CAH ) fatal chronic lifelong disease . Long-term treatment , particular chronic ( over- ) treatment glucocorticoid , may adverse effect cardiovascular risk profile adult CAH patient . The objective study evaluate cardiovascular risk profile adult CAH patient .</brief_summary>
	<brief_title>Cardiovascular Risk Profile Patients With Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description>Treatment glucocorticoid mineralocorticoid change congenital adrenal hyperplasia ( CAH ) fatal chronic lifelong disease . Long-term treatment , particular chronic ( over- ) treatment glucocorticoid , may adverse effect cardiovascular risk profile adult CAH patient . The objective study evaluate cardiovascular risk profile adult CAH patient . DESIGN : Case control study Primary objective : detection cardiovascular damage patient classical non classical CAH diagnose childhood . The patient compare age- gender- tobacco status- match control . Secondary objective Study microvascular function Evaluation cardiovascular risk factor Total cumulative ( TCG ) total average ( TAG ) glucocorticoid dos calculate pediatric adult file correlate arterial macro- microcirculatory dysfunction . Primary outcome Ultrasound evaluation intima-media thickness common carotids , carotid bulb leave ventricular function Secondary outcome Peripheral central blood pressure Skin capillary density pulse-wave velocity Glucose insulin oral glucose tolerance test Circulating cardiovascular risk marker ( hsCRP , adiponectin , Interleukin-6 ) Lipid profile Anthropometry , fat lean mass measure dual-energy X-ray absorptiometry Total cumulative dose glucocorticoid Number subject : 90 patients/90 control Inclusion criterion CAH patient - Patients &gt; 18 yrs classical non classical CAH diagnose childhood - Absence know cardiovascular disease - Absence combined oral contraceptive previous month Inclusion criterion control - Age 18 - Absence know cardiovascular disease - Absence combined oral contraceptive previous month Duration inclusion period : 3 year</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Inclusion criterion : patient Patients &gt; 18 yrs classical non classical CAH diagnose childhood Absence know cardiovascular disease Absence combine oral contraceptive previous month Inclusion criterion : control Age &gt; 18 yrs Absence know cardiovascular disease Absence combine oral contraceptive previous month Exclusion criterion : Blood donation previous 3 month Cardiovascular disease Treatment combine oral contraceptive Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Congenital adrenal hyperplasia ( CAH )</keyword>
	<keyword>Cardiovascular risk</keyword>
	<keyword>Microvascular dysfunction</keyword>
</DOC>